1. Home
  2. ARBK vs MRKR Comparison

ARBK vs MRKR Comparison

Compare ARBK & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Argo Blockchain plc

ARBK

Argo Blockchain plc

HOLD

Current Price

$5.20

Market Cap

14.6M

Sector

Finance

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.38

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARBK
MRKR
Founded
2017
N/A
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
16.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ARBK
MRKR
Price
$5.20
$1.38
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$10.17
AVG Volume (30 Days)
96.7K
336.9K
Earning Date
05-01-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,043,000.00
$4,694,988.00
Revenue This Year
$183.90
N/A
Revenue Next Year
$26.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.24
$0.81
52 Week High
$205.20
$5.95

Technical Indicators

Market Signals
Indicator
ARBK
MRKR
Relative Strength Index (RSI) 76.73 61.12
Support Level $0.12 $1.40
Resistance Level $28.64 $1.48
Average True Range (ATR) 1.74 0.10
MACD 0.56 0.02
Stochastic Oscillator 17.51 76.81

Price Performance

Historical Comparison
ARBK
MRKR

About ARBK Argo Blockchain plc

Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: